SB 86 revises Montana's laws governing automatic external defibrillator (AED) programs. It requires entities (like schools, businesses, or public venues) using AEDs to create written plans detailing AED locations, authorized users, CPR/AED training, coordination with local emergency medical services, and maintenance records. The bill eliminates the Department of Public Health's authority to create rules about AEDs and updates enforcement: violations now trigger a written cease order from the department, with entities able to request a hearing within 30 days. These changes aim to clarify AED program requirements and streamline oversight.
SB 88 revises Montana's certificate of need process for healthcare facilities by requiring the Department of Public Health and Human Services to publish descriptions of letters of intent on the 10th of each month in a newspaper of general circulation and on its website. It establishes a 30-day window for interested parties to request comparative review of proposals and sets clear deadlines for the department to review applications (20 working days for completeness, 90 days for final review). The bill also mandates that the department notify applicants of decisions within 5 working days after the review period ends. These changes directly affect healthcare providers seeking to acquire or expand long-term care facilities, particularly those involving 50% or more of an existing facility. The bill takes effect July 1, 2025.
SB 82 establishes a new program within Montana's Department of Public Health and Human Services to support individuals under age 55 with severe visual impairments in achieving independent living goals. The bill defines "severe visual impairment" as a disability that significantly hinders daily tasks even with correction, and outlines specific services including mobility training, Braille instruction, assistive technology, and peer counseling. Eligibility is determined by the department based on established criteria, with services provided based on available funds and consumer needs, while also guaranteeing a fair hearing for those disagreeing with decisions. The program takes effect July 1, 2025, and applies to Montana residents meeting the defined criteria.
This bill makes Montana's community health aide program permanent by removing its previously scheduled expiration date. It directs the Department of Public Health and Human Services to apply for Medicaid coverage for services provided by certified community health aides. The change directly affects community health aides and their patients, particularly in rural and tribal communities, ensuring continued access to essential healthcare services without future legislative renewal.
HB 195 revises Montana’s cap on non-monetary damages (like pain, suffering, and emotional distress) in medical malpractice cases. It immediately raises the limit from $250,000 to $300,000, with scheduled annual increases: $350,000 in 2026, $400,000 in 2027, $450,000 in 2028, $500,000 in 2029, and 2% annual increases thereafter. The cap applies per patient per incident and is determined by the date the claim was first filed (with the medical panel or in court), not the trial date. This directly affects patients filing medical malpractice claims and healthcare providers defending such cases.
This resolution urges Congress to amend the federal Radiation Exposure Compensation Act (RECA) to include Montanans affected by historical nuclear testing. It specifically highlights that 15 Montana counties (including Meagher, Jefferson, and Gallatin) were heavily exposed during U.S. nuclear tests from 1945-1962, as confirmed by a 1997 government study, yet Montanans remain excluded from RECA compensation. The resolution does not create new policy but formally requests Congress to revise RECA to cover these individuals, who may suffer radiation-related illnesses without access to federal aid. It is a procedural resolution, not a bill, and directs Montana’s Secretary of State to send copies to U.S. lawmakers.
HB 41 adds gabapentin to Montana's Schedule V list of controlled substances under the "depressants" category. This change directly affects medical providers who prescribe gabapentin (used for nerve pain, seizures, and other conditions), pharmacists who dispense it, and patients using the medication. The bill amends Montana Code § 50-32-232 to explicitly include gabapentin - identified by its chemical name "1-(aminomethyl)cyclohexaneacetic acid" - in Schedule V depressants alongside drugs like pregabalin. This policy update standardizes gabapentin's regulatory classification without altering its medical use or prescribing rules.
